Name of Patient

E. M.

Age

32 y.o

Height

52

Diagnosis

Right tubal abortion

Sex

Female

Weight

57 kg

Author

M. M. Olmillo

Website

milkv.co.vu

A/N

youre welcome J

DRUG DATA
Generic Name:
Tranexamic
Acid
Trade name/s:
Cyklokapron,
Hemostan,
Lysteda

CLASSIFICATION
Pharmacologic:
Antifibrinolytic

Therapeutic:
Hemostatic Agent

Patients dose:
1g q8o
Maximum Dose:
1g IV
Minimum Dose:
0.5g IV
Availability:
Tablet: 500mg;
Ampule:
100mg/ml
Route:
IVTT

Pregnancy Category
Risk: B

MECHANISM OF
ACTION

Tranexamic acid
competitively inhibits
activation of
plasminogen (via
binding to the kringle
domain), thereby
reducing conversion
of plasminogen to
plasmin (fibrinolysin),
an enzyme that
degrades fibrin clots,
fibrinogen, and other
plasma proteins,
including the
procoagulant factors
V and VIII
A: 100% bioavailable
with IV administration
D: Penetrates readily
into joint fluid and
synovial membranes
M and E: 95%
excreted unchanged
in urine
Onset: Unknown
Peak: Unknown
Duration: 7-8hours
Drug Half-Life: 6
hours

INDICATIONS

General:
> treatment of
excessive
bleeding resulting
from systemic or
local
hyperfibrinolysis
> prophylaxis in
patients with
coagulopathy
undergoing
surgical
procedures

Patients actual
indication:
Treatment of
excessive
bleeding resulting
from systemic or
local
hyperfibrinolysis

CONTRAINDICATI
ON

> Hypersensitivity
> Active Intravascular
Clotting
> Acquired defective
color vision
> Subarachnoid
Hemorrhage

Precautions:
Use cautiously with renal
impairment, hematuria
originating in the upper
urinary tract; and
conditions associated
with increased thrombus
formation

Interactions:
> drug-drug: concurrent
use of clotting factor
complexes may the
risk of thrombotic
complications (give
tranexamic acid 8 hr
following clotting factor
replacement therapy)

ADVERSE
EFFECTS

CNS: Dizziness
EENT: Visual
abnormalities
CV: Hypotension,
thromboembolism,
thrombosis
GI: Diarrhea,
nausea, vomiting

NURSING
RESPONSIBILITIE
S

Before:
> check the doctors order
> Observe the 15 rights of drug
administration
> Do skin testing
> Tell patient to inform the healthcare
provider if color blind, have a history
of stroke, and blood clot, or bleeding
in your brain.
> Caution patient to avoid products
containing aspirin or NSAIDs
> For women who are taking to
control heavy bleeding, the
medication should only be taken
during the menstrual period
During:
> administer the drug at the right
dosage and route in the right time
> check the patency of the IV site
and IV line
> Do not use this medication without
telling your doctor if you are
breastfeeding a baby
After:
> Advise patient to take medication
exactly as directed
> Unusual change in bleeding pattern
should be reported to the physician
> Report severe allergic reactions
such as rash, hives, itching, dyspnea,
tightness in the chest, swelling of the
mouth, face, lips or tongue
> If the patient missed a dose, let
patient take when remembered, then
take next dose at least 6 hours later.
> Store this medication at room
temperature away from moisture and
heat

Source: 2011
Lippincotts NDG

Source: 2011
Lippincotts NDG

Source: 2011
Lippincotts NDG

Source: 2011
Lippincotts NDG

Source: 2011
Lippincotts NDG

Source: 2011
Lippincotts NDG

Source: 2011 Lippincotts Nursing

Drug Guide